Liver fibrosis progression is uncommon in patients with inactive chronic hepatitis B: A prospective cohort study with paired transient elastography examination

Journal of Gastroenterology and Hepatology (Australia)

Volumn 28, Issue 12, 2013, Pages 1842-1848

  Wong, Grace Lai Hung ^a   Chan, Henry Lik Yuen ^a   Yu, Zhuo ^a   Chan, Hoi Yun ^a   Tse, Chi Hang ^a   Wong, Vincent Wai Sun ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Alanine aminotransferase; Antiviral therapy; HBsAg; HBV DNA; Liver stiffness measurement

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CHRONIC HEPATITIS; COHORT ANALYSIS; DISEASE COURSE; DNA VIRUS; ELASTOGRAPHY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ALANINE AMINOTRANSFERASE; ANTIVIRAL THERAPY; HBSAG; HBV DNA; LIVER STIFFNESS MEASUREMENT;

ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; CARRIER STATE; DISEASE PROGRESSION; DNA, VIRAL; ELASTICITY IMAGING TECHNIQUES; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; VIRAL LOAD;

EID: 84897584248     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12327     Document Type: Article

References (26)

1. Liaw YF, Chu CM. Hepatitis B virus infection. Lancet 2009; 373: 582-592.
2. Wong VW, Chan SL, Mo F etal. Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. J. Clin. Oncol. 2010; 28: 1660-1665.
3. Yuen MF, Tanaka Y, Fong DY etal. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J. Hepatol. 2009; 50: 80-88.
4. Liaw YF, Tai DI, Chu CM, Chen TJ. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology 1988; 8: 493-496.
5. Aube C, Oberti F, Korali N etal. Ultrasonographic diagnosis of hepatic fibrosis or cirrhosis. J. Hepatol. 1999; 30: 472-478.
6. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N. Engl. J. Med. 2001; 344: 495-500.
7. Wong VW, Chan HL. Transient elastography. J. Gastroenterol. Hepatol. 2010; 25: 1726-1731.
8. Chan HL, Wong GL, Choi PC etal. Alanine aminotransferase-based algorithms of liver stiffness measurement by transient elastography (Fibroscan) for liver fibrosis in chronic hepatitis B. J. Viral Hepat. 2009; 16: 36-44.
9. Wong GL, Wong VW, Choi PC etal. Evaluation of alanine transaminase and hepatitis B virus DNA to predict liver cirrhosis in hepatitis B e antigen-negative chronic hepatitis B using transient elastography. Am. J. Gastroenterol. 2008; 103: 3071-3081.
10. Wong GL, Wong VW, Choi PC etal. Clinical factors associated with liver stiffness in hepatitis B e antigen-positive chronic hepatitis B patients. Clin. Gastroenterol. Hepatol. 2009; 7: 227-233.
11. Wong GL, Wong VW, Choi PC etal. On-treatment monitoring of liver fibrosis with transient elastography in chronic hepatitis B patients. Antivir. Ther. 2011; 16: 165-172.
12. Chon YE, Choi EH, Song KJ etal. Performance of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B: a meta-analysis. PLoS One 2012; 7: e44930.
13. Wong GL, Wong VW, Choi PC etal. Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B. Gut 2009; 58: 111-117.
14. European Association For the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B virus infection. J. Hepatol. 2012; 57: 167-185.
15. Liaw YF, Kao JH, Piratvisuth T etal. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol. Int. 2012; 6: 531-561.
16. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-662.
17. Chen YC, Huang SF, Chu CM, Liaw YF. Serial HBV DNA levels in patients with persistently normal transaminase over 10 years following spontaneous HBeAg seroconversion. J. Viral Hepat. 2012; 19: 138-146.
18. Papatheodoridis GV, Manolakopoulos S, Liaw YF, Lok A. Follow-up and indications for liver biopsy in HBeAg-negative chronic hepatitis B virus infection with persistently normal ALT: a systematic review. J. Hepatol. 2012; 57: 196-202.
19. Brunetto MR, Oliveri F, Colombatto P etal. Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. Gastroenterology 2010; 139: 483-490.
20. Chan HL, Wong VW, Wong GL, Tse CH, Chan HY, Sung JJ. A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B. Hepatology 2010; 52: 1232-1241.
21. Chan HL, Chui AK, Lau WY etal. Factors associated with viral breakthrough in lamivudine monoprophylaxis of hepatitis B virus recurrence after liver transplantation. J. Med. Virol. 2002; 68: 182-187.
22. Chan HL, Thompson A, Martinot-Peignoux M etal. Hepatitis B surface antigen quantification: why and how to use it in 2011-a core group report. J. Hepatol. 2011; 55: 1121-1131.
23. Wong GL, Wong VW, Choi PC etal. Assessment of fibrosis by transient elastography compared with liver biopsy and morphometry in chronic liver diseases. Clin. Gastroenterol. Hepatol. 2008; 6: 1027-1035.
24. Tseng TC, Liu CJ, Yang HC etal. Serum hepatitis B surface antigen levels help predict disease progression in patients with low HBV loads. Hepatology 2012; 6: 1027-1035.
25. Chan HL. Identifying hepatitis B carriers at low risk for hepatocellular carcinoma. Gastroenterology 2012; 142: 1057-1060.
26. Tseng TC, Liu CJ, Yang HC etal. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology 2012; 142: 1140-1149.e3; quiz e13-4.